Pipeline
First-in-Class Oral Therapeutics
EB613 for Osteoporosis
EB613 is an oral PTH (1-34) being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low bone mineral density (“BMD”) and high-risk osteoporosis with no prior fracture. We believe EB613 stands as the first program to potentially avail itself of the ASBMR-SABRE BMD endpoint.
EB612 for Hypoparathyroidism
The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement tablet therapy for hypoparathyroidism. We are currently testing new generations of our N-Tab™ Technology with the naked PTH(1-34) peptide to assess the effectiveness of once or twice a day dosing regimens, as well as collaborating with a third party on another peptide in this field.
Collaboration in SBS & Obesity
In September 2023, we entered into a research collaboration with OPKO Biologics, whereby OPKO supplies its proprietary long-acting GLP-2 peptide for short bowel syndrome (SBS) and certain Oxyntomodulin analogs for the development of oral tablet formulations for obesity, using our proprietary N-Tab™ technology.
